Perspective Therapeutics, Inc.
Calidad de datos: 83%
CATX
NYSE
Manufacturing
Chemicals
$4.47
▼
$0.02
(-0.45%)
Cap. Mercado: 509.28 M
Precio
$4.47
Cap. Mercado
509.28 M
Rango del Día
—
Rango de 52 Semanas
—
Volumen
—
Apertura —
Promedio 50D / 200D
—
Promedio 50D / 200D
—
Quick Summary
Puntos Clave
Debt/Equity of 0.01 — conservative balance sheet
Negative free cash flow of -95.23 M
Crecimiento
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Calidad
Return on Equity
-40.61%
Above sector avg (-53.58%)
ROIC-31.37%
Net MarginN/A
Op. MarginN/A
Seguridad
Debt / Equity
0.01
Below sector avg (0.30)
Current Ratio8.66
Interest CoverageN/A
Valoración
PE (TTM|NTM)
-4.94 | -3.81
Below sector avg (-1.48)
P/B Ratio2.10
EV/EBITDAN/A
Dividend YieldN/A
Historial de Precios
Tendencias Financieras
Comparación con Pares
vs mediana del sector Manufacturing (1366 pares)
Comparación con Pares
vs mediana del sector Manufacturing (1366 pares)| Métrica | Acción | Mediana del Sector |
|---|---|---|
| P/E | -4.9 | -1.5 |
| P/B | 2.1 | 1.6 |
| ROE % | -40.6 | -53.6 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.8 |
| D/E | 0.0 | 0.3 |
Precio Objetivo de Analistas
15 analistas
Buy
Actual
$4.47
Objetivo
$13.00
$7.00
$13.00
$18.00
Pronóstico
P/E Futuro
-3.81
EPS Futuro
-$1.17
Ingresos Est.
481,680.0
Estimaciones de Ganancias
| Período | EPS Est. | Ingresos Est. | Analistas |
|---|---|---|---|
| FY2027 |
-$1.17
-$1.39 – -$1.02
|
481,680.0 | 6 |
| FY2026 |
-$1.19
-$1.57 – -$0.91
|
552,080.0 | 9 |
| Período | EPS Est. | Ingresos Est. | Analistas |
|---|---|---|---|
| 2026 Q2 |
-$0.27
-$0.33 – -$0.23
|
115,610.0 | 8 |
| 2026 Q1 |
-$0.30
-$0.37 – -$0.26
|
137,180.0 | 8 |
Sorpresas de Ganancias
Últimos 4 trimestres
| Trimestre | EPS Est. | EPS Real | Sorpresa |
|---|---|---|---|
| Q42025 | -$0.35 | -$0.51 | -45.6% |
| Q32025 | -$0.32 | -$0.35 | -8.8% |
| Q22025 | -$0.29 | -$0.30 | -3.3% |
| Q12025 | -$0.27 | -$0.25 | +7.9% |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -103.12 M |
| ROE | -40.61% | ROA | -34.06% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -95.23 M |
| ROIC | -31.37% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0.01 | Current Ratio | 8.66 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 157.88 M | Tangible Book Value | 242.22 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -4.94 | Forward P/E | -3.81 |
| P/B Ratio | 2.10 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | 1057.30 | Fwd Earnings Yield | N/A |
| FCF Yield | -18.70% | ||
| Market Cap | 509.28 M | Enterprise Value | 484.16 M |
| Per Share | |||
| EPS (Diluted TTM) | -1.40 | Revenue / Share | N/A |
| FCF / Share | -0.84 | OCF / Share | -0.72 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 92.35% |
| SBC-Adj. FCF | -102.55 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | 2.51 M | 2.71 M |
| Net Income | -103.12 M | -79.28 M | -46.51 M | -7.27 M | -3.39 M |
| EPS (Diluted) | -1.40 | -1.23 | — | — | — |
| Gross Profit | — | — | 1.43 M | 4.62 M | 5.12 M |
| Operating Income | -113.56 M | -90.89 M | -40.94 M | -7.39 M | -3.45 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 84.22 M | 41.64 M | 21.31 M | 2.58 M | 1.43 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 3.25 M | 2.31 M | — | — | — |
| Interest Expense | — | — | 84,000.0 | — | — |
| Income Tax | -793,000.0 | -2.10 M | -2.65 M | 0.0 | 0.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 266.97 M | 341.10 M | 97.89 M | 64.44 M | 70.42 M |
| Total Liabilities | 59.94 M | 50.43 M | 22.71 M | 3.16 M | 3.01 M |
| Shareholders' Equity | 207.03 M | 290.67 M | 75.18 M | 61.28 M | 67.41 M |
| Total Debt | 1.63 M | 1.68 M | 1.73 M | — | — |
| Cash & Equivalents | 30.63 M | 61.58 M | 9.24 M | 55.89 M | 63.83 M |
| Current Assets | 148.39 M | 231.16 M | 16.84 M | 59.33 M | 67.30 M |
| Current Liabilities | 28.68 M | 18.23 M | 15.66 M | 2.27 M | 1.80 M |
{"event":"ticker_viewed","properties":{"ticker":"CATX","listing_kind":"stock","pathname":"/stocks/catx","exchange":"NYSE","country":"US"}}


